Difficulties in diagnosing intestinal T-cell lymphoma. Case report
- 作者: Gadaev I.1, Ershov V.1, Kovrigina A.2, Sokolova I.1, Tashyan O.1, Mingalimov M.1, Antyufeeva O.1, Budanova D.1, Mnatsakanyan M.1, Bochkarnikova O.1, Nagornaia D.1
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- National Medical Research Center for Hematology
- 期: 卷 95, 编号 2 (2023)
- 页面: 180-186
- 栏目: Clinical notes
- URL: https://journals.rcsi.science/0040-3660/article/view/132903
- DOI: https://doi.org/10.26442/00403660.2023.02.202060
- ID: 132903
如何引用文章
全文:
详细
The article describes a rare diagnosis of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), due to its veiled by a number of so-called “masks” of enteropathies. A detailed analysis of all clinical, morphological and immunohistochemical data made it possible to establish the correct diagnosis. The revealed pathology is extremely rare in practice, even among specialists in hematology. The article demonstrates the main stages of both a complex diagnosis and an attempt at therapy for this aggressive form of intestinal lymphoma.
作者简介
Igor Gadaev
Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0002-2782-4179
канд. мед. наук, доц., доц. каф. госпитальной терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowVladimir Ershov
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0002-8641-1489
д-р мед. наук, проф. каф. госпитальной терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowAlla Kovrigina
National Medical Research Center for Hematology
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0002-1082-8659
д-р биол. наук, проф., зав. отд. патологической анатомии
俄罗斯联邦, MoscowIrina Sokolova
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0002-8884-1087
врач-гематолог высш. категории гематологического отд. клиники Госпитальной терапии им. А.А. Остроумова УКБ №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowOlga Tashyan
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0001-6759-6820
канд. мед. наук, ассистент каф. госпитальной терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowMarat Mingalimov
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0002-8491-2140
клинический ординатор каф. госпитальной терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowOlga Antyufeeva
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0003-4268-3076
врач-гематолог гематологического отд. клиники Госпитальной терапии им. А.А. Остроумова УКБ №1, ассистент каф. госпитальной терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowDarya Budanova
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0001-6324-2371
канд. мед. наук, врач-гематолог гематологического отд. клиники Госпитальной терапии им. А.А. Остроумова УКБ №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowMarina Mnatsakanyan
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0001-9337-7453
д-р мед. наук, проф. каф. госпитальной терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowOlga Bochkarnikova
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0001-9316-6920
зав. гематологическим отд. клиники Госпитальной терапии им. А.А. Остроумова УКБ №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowDaria Nagornaia
Sechenov First Moscow State Medical University (Sechenov University)
Email: doktor-gai@yandex.ru
ORCID iD: 0000-0002-2490-6371
клинический ординатор каф. госпитальной терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, Moscow参考
- Chan JKC, Fukuyama M. Haematolymphoidtumours of the digestive system. In: WHO Classification of Tumours Editorial Board. WHO classification of tumours of the digestive system. 5th ed. Vol 1. Lyon: IARC, 2019.
- van Vliet С, Spagnolo DV. T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update. Pathology. 2020;52(1):128-41. doi: 10.1016/j.pathol.2019.10.001
- Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148-55. doi: 10.1182/blood-2011-02-335216
- Jaffe ES, Chott A, Ott G, et al. Intestinal T-cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Ed. SH Swerdlow, E Campo, NL Harris, et al. Revised. 4th ed. Lyon: IARC, 2017.
- Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 2011;117:1447-52. doi: 10.1182/blood-2010-08-302737
- Xiao W, Gupta GK, Yao J, et al. Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood. 2019;134:986-91. doi: 10.1182/blood.2019001443
- Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 2010;116:5631-7. doi: 10.1182/blood-2010-06-290650
- Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795-803. doi: 10.1200/JCO.2000.18.4.795
- Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87:663-8. doi: 10.1002/ajh.23213
- Tan SY, Chuang SS, Tang T, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 2013;27:1688-96. doi: 10.1038/leu.2013.41
- Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664-70. doi: 10.1182/blood-2009-07-231324
- Silano M, Volta U, De Vincenzi A, Dessi MDM. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53:972-6. doi: 10.1007/s10620-007-9952-8
- Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease. Ann Intern Med. 2013;159:169-75. doi: 10.7326/0003-4819-159-3-201308060-00006
- Foukas PG, de Leval L. Recent advances in intestinal lymphomas. Histopathology. 2015;66:112-36. doi: 10.1111/his.12596
- Arps DP, Smith LB. Classic versus type II enteropathy-associated T-cell lymphoma: diagnostic considerations. Arch Pathol Lab Med. 2013;137:1227-31. doi: 10.5858/arpa.2013-0242-CR
- Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377-84. doi: 10.1016/j.dld.2012.12.001
- Ondrejka S, Jagadeesh D. Enteropathy-associated T-cell lymphoma. Curr Hematol Malig R. 2016;11:504-13. doi: 10.1007/s11899-016-0357-7
- Nicolae A, Xi L, Pham TH, et al. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30:2245-7. doi: 10.1038/leu.2016.178
- Attygalle AD, Cabeçadas J, Gaulard P, et al. Peripheral T-cell and NKcell lymphomas and their mimics; taking a step forward – report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64:171-99. doi: 10.1111/his.12251
- Kikuma K, Yamada K, Nakamura S, et al. Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol. 2014;45:1276-84. doi: 10.1016/j.humpath.2013.10.038
- Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35:1557-69. doi: 10.1097/PAS.0b013e318222dfcd
- Ko YH, Karnan S, Kim KM, et al. Enteropathy-associated T-cell lymphoma – a clinicopathologic and array comparative genomic hybridization study. Hum Pathol. 2010;41:1231-7. doi: 10.1016/j.humpath.2009.11.020
- Tomita S, Kikuti YY, Carreras J, et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015;28:1286-96. doi: 10.1038/modpathol.2015.85
- Isaacson PGT, Bhagat G. Enteropathy-associated T-cell lymphoma and other primary intestinal T-cell lymphomas. In: Jaffe ES, Arber DA, Campo E, et al., ed. Hematopathology. 2nd ed. Philadelphia: Elsevier, 2017.
- Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol. 1998;153:1483-90. doi: 10.1016/S0002-9440(10)65736-7
- Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214:1371-86. doi: 10.1084/jem.20160894
- Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated Tcell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602. doi: 10.1038/ncomms12602
- Lamure S, Duléry R, Di Blasi R, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. E Clinical Medicine. 2020;27:100549.
- Challenor S, Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192:415. doi: 10.1111/bjh.17116
- de la Cruz-Benito B, Lázaro-Del Campo P, Ramírez-López A, et al. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020;191:386-9. doi: 10.1111/bjh.17066
- Lang N, Kuruvilla J. Evolving management strategies for lymphomas during the COVID-19 pandemic. Leuk Lymphoma. 2020:1-19. doi: 10.1080/10428194.2020
- Perini GF, Fischer T, Gaiolla RD, et al. Hemoterapia e TerapiaCelular (ABHH) How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell Ther. 2020;42:103-10. doi: 10.1016/j.htct.2020.04.002
- Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192:1100-5.